<DOC>
	<DOCNO>NCT01245166</DOCNO>
	<brief_summary>Type 2 diabetes mellitus chronic metabolic disorder cause insulin secretion deficiency insulin action defect . In type subject , fast hyperglycemia result elevate rate basal hepatic glucose production , coexist hyperinsulinemia.After meal , impair control hepatic glucose production insulin decrease insulin-mediated glucose uptake muscle contribute nearly equally postprandial hyperglycemia ( Scheen , 1997 ) . Type 2 diabetic subject experience significant morbidity mortality microvascular ( retinopathy , nephropathy , neuropathy ) macrovascular ( cardiovascular disease , stroke , peripheral vascular disease ) complication . The appropriate treatment good glycemic control diabetes therefore important necessary ( Vaag , 2006 ) . Evidences suggest combination therapy use oral antidiabetic agent different mechanism action may effective achieve maintain target blood glucose level ( Turner et al. , 2005 ) .There five class oral antihyperglycemic agent ( sulfonylurea , biguanides , α- ucosidase inhibitor , thiazolidinediones meglitinides ) currently available improve glycemic control subject type 2 diabetes , work different mechanism action . Metformin , biguanide insulin-sensitizing property , use alone combination class agent . Metformin currently first-choice treatment subject diagnose type 2 diabetic subject obesity , characterize insulin-resistance . Metformin also provide reduction body weight ameliorates lipid abnormality think related reduction hepatic gluconeogenesis ( Hundal &amp; Inzucchi , 2003 ) .Acarbose , α-glucosidase inhibitor , approve treatment type 2 diabetes , first approve prediabetes treatment ( Chiasson et al. , 1994 ; Breuer , 2003 ; Chiasson et al. , 2002 ) . The drug launch worldwide type 2 diabetes monotherapy combination therapy 1990 proven efficacious first-line therapy ( Coniff et al. , 1995 ) combination sulfonylureas insulin ( Kelley et al. , 1998 ) . Acarbose metformin associate beneficial effect hyperglycemia , hyperinsulinemia , body weight , , study , triglyceride level ( Krentz et al. , 1994 ) . Because factor part cluster risk factor cardiovascular disease , combine two drug may useful . In long-term clinical study , acarbose show favorable safety profile ( Hasche et al. , 1999 ) .In combination metformin , acarbose show improve long-term glycemic control ( Rosenstock et al. , 1998 ; Halimi et al. , 2000 ) . This study conduct vestigation efficacy safety concurrent use acarbose metformin type 2 diabetes mellitus subjects.Lotus Pharmaceutical Co. , Ltd. intend initiate Phase III program investigate ass efficacy safety metformin combination acarbose type 2 diabetes mellitus subject consider inadequately blood glucose control . Since combination tablet acarbose metformin yet approve Taiwan DOH , study conduct evaluate efficacy safety combination tablet acarbose metformin treatment type 2 diabetes mellitus subject Taiwan . Acarbose chosen active-comparator .</brief_summary>
	<brief_title>A Phase III Randomized , Double-blind , Parallel-group Study Evaluate Efficacy Safety Acarmet ( Metformin HCl 500 mg Plus Acarbose 50 mg Tablets ) Versus Acarbose Alone Subjects With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Subjects may include study meet follow criterion : 1 . Male female subject age ≥ 20 ≤ 80 year old ; 2 . Subject type 2 diabetes mellitus ; 3 . Subject document HbA1c ≥ 7 % ≤ 10 % within 3 month prior study screen ; 4 . Body mass index &lt; 35 kg/m2 ; 5 . Subject willing able comply study procedure sign inform consent . Subjects exclude study follow reason : 1 . Subject type 1 diabetes secondary diabetes ; 2 . Subject history concurrent ketonuria acidosis ; 3 . Subject type 2 diabetes mellitus treat high dose sulfonylurea ( gliclazide &gt; 320 mg , glibenclamide &gt; 20 mg , glimepiride &gt; 6 mg , glipizide &gt; 20 mg ) biguanides ( metformin &gt; 2000 mg ) , αglucosidase inhibitor ( acarbose &gt; 300 mg ) , meglitinides ( repaglinide &gt; 6 mg nateglinide &gt; 360 mg ) , thiazolidinedione ( rosiglitazone &gt; 4 mg , pioglitazone &gt; 30 mg ) insulin ; 4 . Subject gastrointestinal disease may interfere absorption investigational product discretion investigator , include limited malabsorption syndrome gastric ulcer ; 5 . Subject kidney function impairment define serum creatinine &gt; 1.5 mg/dL male , serum creatinine &gt; 1.4 mg/dL female , liver function impairment define ALT &gt; 3 X ULN , AST &gt; 3 X ULN ; 6 . Subject history drug alcohol abuse within past 1 year ; 7 . Subject diagnose acute myocardial infarction cardiac failure within 6 month precede screening ; 8 . Subject hypersensitivity acarbose and/or metformin product ; 9 . Subject active cancer , define ongoing , progress cancer , &lt; 5 year stable disease ; 10 . Hemoglobin value &lt; 10 gm/dl female &lt; 11 gm/dl male ; 11 . Female subject childbearing potential : lactating ; · positive urine pregnancy test Visit 1 ; refuse adopt reliable method contraception study ; 12 . Subject contraindicate acarbose and/or metformin treatment ; 13 . Subject receive investigational agent within 28 day prior first dose investigational product ; 14 . Subject history evidence medical condition would expose undue risk significant adverse event course trial , include limited hepatic , renal , respiratory , cardiovascular , endocrine , immune , neurological , hematological disease determine clinical judgment investigator .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>